Y-90 radiation plus immunotherapy and chemo for bile duct cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial studies whether combining Y-90 liver radiation with an immunotherapy drug (durvalumab) and chemo (gemcitabine and cisplatin) can better control locally advanced or metastatic intrahepatic cholangiocarcinoma (bile duct cancer in the liver). It may help shrink tumors and slow disease growth, depending on how well the treatment works for your cancer type and overall health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and able to understand the study and sign consent.
- You have bile duct cancer in the liver that cannot be removed by surgery (locally advanced) or has spread, and at least one visible liver tumor area.
- Your scans (CT or MRI) show measurable disease that matches the study’s criteria.
- Your general health is good enough for treatment (ECOG score 1 or less) and you are expected to live at least 12 more weeks.
- Blood tests and organ function are adequate (blood counts, kidney function, and liver function within set limits).
- You can safely receive Y-90 treatment per the interventional radiology assessment (for example, no anatomy that would push radiation harm to the lungs).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of radiation therapy (PULSAR), immunotherapy, and chemotherapy for advanced bile duct cancer. It aims to see if this approach can shrink tumors and improve survival.
This trial tests combining immunotherapy (anti-PD-1/PD-L1 antibodies) with standard chemotherapy (gemcitabine and cisplatin) for people with advanced bile duct or gallbladder cancer that can't be removed by surgery. The goal is to see if this combination works better than chemo alone.
This trial tests a combination of chemotherapy, immunotherapy, and heat therapy (hyperthermia) with a special radiation technique for advanced bile duct or gallbladder cancer that hasn't been treated before. It aims to see if this combination can help shrink tumors and improve outcomes.
This trial tests a combination of a new immunotherapy drug (cadonilimab) with three chemotherapy drugs for advanced bile duct or gallbladder cancer that has already been treated with gemcitabine. The goal is to see if adding immunotherapy helps control the cancer better.
This Phase 2 study tests whether combining chemotherapy (gemcitabine and cisplatin) and an immunotherapy drug (durvalumab) with targeted Y-90 radiation can shrink inoperable intrahepatic cholangiocarcinoma tumors. It’s looking for better tumor shrinking and improved cancer control.
This trial tests combining a targeted radiation treatment (radioembolization) with two immunotherapy drugs (tremelimumab and durvalumab) for people with advanced intrahepatic cholangiocarcinoma that cannot be removed by surgery. It aims to shrink tumors and control cancer spread to lymph nodes or one other organ.
Hear when a new Bile Duct Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.